Pasireotide acetate is a synthetic cyclic octapeptide and a somatostatin analog, primarily used in the treatment of acromegaly and Cushing's disease. It functions by binding to somatostatin receptors, particularly subtype 5, which inhibits the secretion of growth hormone and adrenocorticotropic hormone (ACTH). This action helps to reduce hormone levels in patients with these conditions. Pasireotide acetate is typically administered via subcutaneous injection and has a relatively long half-life, allowing for less frequent dosing compared to other treatments. The compound is characterized by its complex structure, which includes multiple amino acids arranged in a specific sequence that contributes to its biological activity. Additionally, it is soluble in water and exhibits stability under various conditions, making it suitable for pharmaceutical formulations. Side effects may include gastrointestinal disturbances, hyperglycemia, and potential impacts on liver function, necessitating monitoring during treatment. Overall, pasireotide acetate represents a significant advancement in the management of hormone-related disorders.

Pasireotide Acetate

396091-76-2: Pasireotide acetate is a synthetic cyclic octapeptide and a somatostatin analog, primarily used in the treatment of acromegaly and Cushing's disease. It functions by binding to somatostatin receptors, particularly subtype 5, which inhibits the secretion of growth hormone and adrenocorticotropic hormone (ACTH). This action helps to reduce hormone levels in patients with these conditions. Pasireotide acetate is typically administered via subcutaneous injection and has a relatively long half-life, allowing for less frequent dosing compared to other treatments. The compound is characterized by its complex structure, which includes multiple amino acids arranged in a specific sequence that contributes to its biological activity. Additionally, it is soluble in water and exhibits stability under various conditions, making it suitable for pharmaceutical formulations. Side effects may include gastrointestinal disturbances, hyperglycemia, and potential impacts on liver function, necessitating monitoring during treatment. Overall, pasireotide acetate represents a significant advancement in the management of hormone-related disorders.

The pKi of Pasireotide (SOM230) acetate for sst1, 2, 3, 4, and 5 were 8.2, 9.0, 9.1, less than 7.0, and 9.9, respectively.Cost-effective and quality-assured.

CAS 396091-76-2

Pasireotide Acetate

Pasireotide Acetate

Ref: 54-BUP01285

Pasireotide Acetate

Ref: TM-TP2207